NYSE:NSPR InspireMD (NSPR) Stock Price, News & Analysis $2.27 -0.02 (-0.87%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About InspireMD Stock (NYSE:NSPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get InspireMD alerts:Sign Up Key Stats Today's Range$2.24▼$2.3350-Day Range$2.19▼$2.7052-Week Range$1.99▼$3.80Volume141,804 shsAverage Volume65,627 shsMarket Capitalization$69.54 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingBuy Company OverviewInspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.Read More… InspireMD Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks63rd Percentile Overall ScoreNSPR MarketRank™: InspireMD scored higher than 63% of companies evaluated by MarketBeat, and ranked 394th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInspireMD has only been the subject of 1 research reports in the past 90 days.Read more about InspireMD's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of InspireMD is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of InspireMD is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInspireMD has a P/B Ratio of 1.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.07% of the float of InspireMD has been sold short.Short Interest Ratio / Days to CoverInspireMD has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InspireMD has recently decreased by 4.40%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInspireMD does not currently pay a dividend.Dividend GrowthInspireMD does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.07% of the float of InspireMD has been sold short.Short Interest Ratio / Days to CoverInspireMD has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InspireMD has recently decreased by 4.40%, indicating that investor sentiment is improving. News and Social Media2.0 / 5News Sentiment0.66 News SentimentInspireMD has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for InspireMD this week, compared to 2 articles on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InspireMD insiders have not sold or bought any company stock.Percentage Held by Insiders29.72% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about InspireMD's insider trading history. Receive NSPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InspireMD and its competitors with MarketBeat's FREE daily newsletter. Email Address NSPR Stock News HeadlinesInspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke - MorningstarJune 26, 2025 | morningstar.comMInspireMD Inc.: InspireMD Announces FDA Approval for CGuard Prime Carotid Stent System for the Prevention of StrokeJune 25, 2025 | finanznachrichten.deI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.June 30 at 2:00 AM | Porter & Company (Ad)InspireMD Stock Surges on FDA Approval for CGuard StentJune 24, 2025 | marketwatch.comInspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of StrokeJune 24, 2025 | globenewswire.comInspireMD Announces CE Mark Approval For CGuard Prime Embolic Prevention SystemJune 15, 2025 | nasdaq.comInspireMD, Inc. Secures CE Mark Approval for CGuard® Prime EPS Carotid Stent SystemJune 15, 2025 | nasdaq.comInspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of StrokeJune 13, 2025 | globenewswire.comSee More Headlines NSPR Stock Analysis - Frequently Asked Questions How have NSPR shares performed this year? InspireMD's stock was trading at $2.63 at the start of the year. Since then, NSPR shares have decreased by 13.7% and is now trading at $2.27. View the best growth stocks for 2025 here. How were InspireMD's earnings last quarter? InspireMD, Inc. (NYSE:NSPR) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. The company earned $1.81 million during the quarter, compared to the consensus estimate of $1.74 million. InspireMD had a negative net margin of 413.96% and a negative trailing twelve-month return on equity of 69.42%. How do I buy shares of InspireMD? Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InspireMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings11/12/2024Today6/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:NSPR CIK1433607 Webwww.inspiremd.com Phone9728887766804FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$5.00 Low Stock Price Target$4.00 Potential Upside/Downside+94.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.92 million Net Margins-413.96% Pretax Margin-413.00% Return on Equity-69.42% Return on Assets-57.68% Debt Debt-to-Equity RatioN/A Current Ratio6.39 Quick Ratio6.05 Sales & Book Value Annual Sales$7.03 million Price / Sales10.07 Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book1.26Miscellaneous Outstanding Shares30,635,000Free Float18,332,000Market Cap$70.77 million OptionableOptionable Beta0.59 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:NSPR) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InspireMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InspireMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.